MCID: ACT114
MIFTS: 33

Acute Myeloblastic Leukemia Without Maturation

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Acute Myeloblastic Leukemia Without Maturation

MalaCards integrated aliases for Acute Myeloblastic Leukemia Without Maturation:

Name: Acute Myeloblastic Leukemia Without Maturation 52 58 17
Acute Myeloblastic Leukemia M1 52 58
Aml M1 52 58
Acute Myeloblastic Leukemia Type 1 52

Characteristics:

Orphanet epidemiological data:

58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 C92.0
UMLS via Orphanet 72 C0026998
Orphanet 58 ORPHA98833

Summaries for Acute Myeloblastic Leukemia Without Maturation

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 98833 Definition A rare, acute myeloid leukemia characterized by no significant myeloid maturation and more than 90% blast cells in the non-erythroid population. Various degrees of anemia , thrombocytopenia , or pancytopenia are present. Frequent clinical manifestations include fatigue, fever, bleeding disorders, and organomegaly, especially hepatosplenomegaly . Visit the Orphanet disease page for more resources.

MalaCards based summary : Acute Myeloblastic Leukemia Without Maturation, also known as acute myeloblastic leukemia m1, is related to leukemia and myeloid leukemia. An important gene associated with Acute Myeloblastic Leukemia Without Maturation is FLT3 (Fms Related Receptor Tyrosine Kinase 3), and among its related pathways/superpathways is Tyrosine Kinases / Adaptors. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow.

Wikipedia : 74 Acute myeloblastic leukemia without maturation is a quickly progressing disease in which too many... more...

Related Diseases for Acute Myeloblastic Leukemia Without Maturation

Graphical network of the top 20 diseases related to Acute Myeloblastic Leukemia Without Maturation:



Diseases related to Acute Myeloblastic Leukemia Without Maturation

Symptoms & Phenotypes for Acute Myeloblastic Leukemia Without Maturation

Drugs & Therapeutics for Acute Myeloblastic Leukemia Without Maturation

Drugs for Acute Myeloblastic Leukemia Without Maturation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4 6055-19-2, 50-18-0 2907
3
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
4 Immunosuppressive Agents Phase 4
5 Immunologic Factors Phase 4
6 Alkylating Agents Phase 4
7 Antilymphocyte Serum Phase 4
8 Antirheumatic Agents Phase 4
9
Mesna Approved, Investigational Phase 3 3375-50-6 598
10
Idarubicin Approved Phase 3 58957-92-9 42890
11
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
12
Etoposide Approved Phase 3 33419-42-0 36462
13
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
14
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
15
Melphalan Approved Phase 3 148-82-3 4053 460612
16
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
17
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
18
leucovorin Approved Phase 3 58-05-9 6006 143
19
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
20
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
21
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
22
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
23
Fludarabine Approved Phase 2, Phase 3 21679-14-1, 75607-67-9 30751
24
Carmustine Approved, Investigational Phase 3 154-93-8 2578
25
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
26
Thioguanine Approved Phase 3 154-42-7 2723601
27
Hydroxyurea Approved Phase 3 127-07-1 3657
28
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
29
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
30
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
31
Daunorubicin Approved Phase 3 20830-81-3 30323
32
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
33
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
34
midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
35
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
36
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
37 Lintuzumab Investigational Phase 3 166089-32-3
38
tipifarnib Investigational Phase 2, Phase 3 192185-72-1 159324
39 Staurosporine Experimental Phase 3 62996-74-1
40 Antibodies, Monoclonal Phase 3
41 Antibodies Phase 3
42 Immunoglobulins Phase 3
43 Vaccines Phase 3
44 Antineoplastic Agents, Immunological Phase 3
45 Gemtuzumab Phase 3
46 Anti-Retroviral Agents Phase 3
47 Analgesics, Non-Narcotic Phase 3
48 Analgesics Phase 3
49 Interleukin-2 Phase 3
50 Anti-HIV Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study Unknown status NCT00454168 Phase 3
3 Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
4 RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
5 Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML) Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
6 The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
7 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
8 A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission Completed NCT00006223 Phase 3
9 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
10 High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
11 RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
12 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
13 A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse Completed NCT00112554 Phase 3 cytarabine;laromustine
14 Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
15 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
16 Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
17 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
18 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
19 A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
20 A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
21 A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
22 A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
23 Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
24 Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
25 Phase II, Open-Label Study of HuM195 (Humanized Anti-CD33 Monoclonal Antibody) Administered to Patients With Acute Myelogenous Leukemia (AML) Who Are Documented Regimen Failures (RF) of the Control Arm of Study 195-301 Unknown status NCT00006084 Phase 2
26 A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
27 Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial) Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
28 Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study Completed NCT00004899 Phase 2 busulfan;etoposide
29 Evaluation of Allogeneic Peripheral Blood Stem Cell Transplants From a Related Donor Without Graft-Versus-Host Prophylaxis in Patients With High Risk of Relapse Completed NCT00003396 Phase 2 cyclophosphamide;melphalan
30 5-Azacytidine to Treat Acute Myeloid Leukemia in Elderly or Frail Patients Not Suitable for Intensive Chemotherapy. A Multicenter Phase II Trial. Completed NCT00739388 Phase 2 azacytidine
31 Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML) Completed NCT00528398 Phase 2 cytarabine;idarubicin
32 PHASE II STUDY EVALUATING AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR ACUTE LEUKEMIAS Completed NCT00002567 Phase 2 etoposide
33 Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old Completed NCT00005795 Phase 2 arsenic trioxide
34 A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia Completed NCT01656031 Phase 2 clofarabine;cytarabine
35 A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML Completed NCT00425477 Phase 2 bexarotene
36 Pilot Study of Sodium Phenylbutyrate Plus Azacytidine Completed NCT00006019 Phase 2 azacitidine;sodium phenylbutyrate
37 A Phase II Study of Allografting to Establish Mixed or Full Donor Chimerism as Consolidative Immunotherapy for Older Patients With AML in Complete Remission Using Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00005801 Phase 2
38 Phase II Study of High-Dose Busulfan and Cyclophosphamide Followed by Allogeneic Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia Completed NCT00004896 Phase 2 busulfan;cyclophosphamide
39 Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia: A POG Phase II Study Completed NCT00003178 Phase 2 cladribine;idarubicin
40 A Phase II Trial Combining Gemtuzumab Ozogamicin (Mylotarg) With Cyclosporine for the Treatment of Relapsed Acute Myeloid Leukemia in Adults Over Age 60 Completed NCT00089050 Phase 2 cyclosporine;gemtuzumab ozogamicin
41 A Phase II Study Of Daunomycin And ARA-C, Both Given By Continous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older Completed NCT00023777 Phase 2 cytarabine;daunorubicin hydrochloride
42 A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose ARA-C for Patients With Relapsed Acute Myeloid Leukemia (AML) Completed NCT00049179 Phase 2 cytarabine;gemtuzumab ozogamicin
43 ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA Completed NCT00002547 Phase 2 busulfan;cyclophosphamide;cyclosporine;cytarabine;methotrexate
44 A Phase I/II Study of CLOLAR® (Clofarabine, IND# 73, 789) in Combination With Cytarabine in Pediatric Patients With Refractory/Relapsed Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
45 Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myelogenous Leukemia in Remission Using HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors, or HLA-Mismatched Familial Donors - A Phase 2 Study Completed NCT01020734 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate
46 An Open Label Phase II Trial of Clofarabine and Temsirolimus in Older Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Completed NCT00775593 Phase 2 clofarabine;temsirolimus
47 AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY Completed NCT00002768 Phase 2 busulfan;cytarabine;etoposide;methotrexate
48 A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous Leukemia Completed NCT00005962 Phase 2 cyclophosphamide;cytarabine;gemtuzumab ozogamicin;liposomal daunorubicin citrate;topotecan hydrochloride
49 A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide (DATE) for De Novo AML: In the Treatment of Young Patients Ages 16-59 Completed NCT00005793 Phase 1, Phase 2 Cytarabine;Daunorubicin;Etoposide;Topotecan
50 A Phase II Study of Daunomycin and ARA-C Given by Continuous IV Infusion With PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older Completed NCT00004217 Phase 2 cytarabine;daunorubicin hydrochloride;valspodar

Search NIH Clinical Center for Acute Myeloblastic Leukemia Without Maturation

Genetic Tests for Acute Myeloblastic Leukemia Without Maturation

Anatomical Context for Acute Myeloblastic Leukemia Without Maturation

MalaCards organs/tissues related to Acute Myeloblastic Leukemia Without Maturation:

40
Myeloid, Bone, Bone Marrow, T Cells, Monocytes, Neutrophil, Lymph Node

Publications for Acute Myeloblastic Leukemia Without Maturation

Articles related to Acute Myeloblastic Leukemia Without Maturation:

(show top 50) (show all 192)
# Title Authors PMID Year
1
Morphological characteristics, cytogenetic profile, and outcome of RUNX1-RUNX1T1-positive acute myeloid leukemia: Experience of an Indian tertiary care center. 61
31725954 2019
2
Challenges associated with limited-resources cancer care facility: Bilateral breast myeloid sarcoma as an example. 61
31788245 2019
3
Role of CD71 in acute leukemia- An immunophenotypic marker for erythroid lineage or proliferation? 61
31361230 2019
4
Detection of a novel CBFB-MYH11 fusion transcript in acute myeloid leukemia M1 with inv(16)(p13q22). 61
31353165 2019
5
[Analysis of CDSS Experimental Indexes in 333 Cases of Newly Diagnosed Acute Leukemia]. 61
31204913 2019
6
lncRNA PCAT-1 interacting with FZD6 contributes to the malignancy of acute myeloid leukemia cells through activating Wnt/β-catenin signaling pathway. 61
31814913 2019
7
[Expression of EVI1 in Bone Marrow of Patients with AML and ALL and Its Correlation with Leukemia Subtyping, Clinical Features and Prognosis of Patients]. 61
30295245 2018
8
[Analysis of Clinical and Laboratory Features of Patients with Acute Myeloid Leukemia(AML)-M1/M2 with Cuplike Nuclei Morphology]. 61
30111391 2018
9
Cup-like Blasts in 2 Pediatric Patients With NPM-1-Positive Acute Myeloid Leukemia. 61
29432313 2018
10
Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission. 61
29243031 2018
11
Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR. 61
29286103 2018
12
Down syndrome associated childhood myeloid leukemia with yet unreported acquired chromosomal abnormalities and a new potential adverse marker: dup(1)(q25q44). 61
29563973 2018
13
A new adult AML case with an extremely complex karyotype, remission and relapse combined with high hyperdiploidy of a normal chromosome set in secondary AML. 61
30186609 2018
14
A transient cutaneous relapse of AML M1 in hematological remission: a case report. 61
29264902 2017
15
[FLT3 Gene Expression and Its Clinical Significance in Acute Myeloid Leukemia.] 61
28598126 2016
16
Immunohistochemical Detection of NPM1 Mutation in Acute Myeloid Leukemia and its Association With Cup-like Nuclear Morphology of Blasts. 61
26200838 2016
17
Acute Myeloid Leukemia: Clinical Spectrum of 125 Patients. 61
26838239 2016
18
A Case Report of Concurrent IDH1 and NPM1 Mutations in a Novel t(X;2)(q28;p22) Translocation in Acute Myeloid Leukaemia without Maturation (AML-M1). 61
28239274 2015
19
Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia. 61
25825260 2015
20
[Expression of CD71 on cell proliferation in hematologic malignancy and its correlation with Ki-67]. 61
25687079 2015
21
Pediatric donor cell leukemia after allogeneic hematopoietic stem cell transplantation in AML patient from related donor. 61
25674158 2015
22
[An unusual cause of febrile neutropenia: brucellosis]. 61
25492662 2014
23
Geographic heterogeneity of the AML1-ETO fusion gene in Iranian patients with acute myeloid leukemia. 61
26989731 2014
24
[Clinical characteristics and therapeutic efficacy of normal karyotype AML patients with CEBPA mutation]. 61
24598643 2014
25
Esterase D and gamma 1 actin level might predict results of induction therapy in patients with acute myeloid leukemia without and with maturation. 61
24085543 2013
26
Novel t(7;10)(p22;p24) along with NPM1 mutation in patient with relapsed acute myeloid leukemia. 61
24413869 2013
27
MiR-99a may serve as a potential oncogene in pediatric myeloid leukemia. 61
24191888 2013
28
KLF4 translation level is associated with differentiation stage of different pediatric leukemias in both cell lines and primary samples. 61
22592916 2013
29
Identification of homogeneously staining regions in leukemia patients. 61
24124438 2013
30
Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia. 61
23238897 2013
31
[Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation]. 61
23755812 2013
32
The Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patients. 61
24376688 2013
33
Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. 61
23027709 2013
34
A New Case of dic(1;15)(p11;p11) in AML M1: Apropos of a Case and a Review of the Literature. 61
23533845 2013
35
A novel RUNX1-C11orf41 fusion gene in a case of acute myeloid leukemia with a t(11;21)(p14;q22). 61
23102734 2012
36
Comparative proteome analysis of acute myeloid leukemia with and without maturation. 61
22850270 2012
37
Acute myeloblastic leukemia with associated BCR-ABL translocation in a dog. 61
22747755 2012
38
Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. 61
22539801 2012
39
Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical prognosis. 61
22674781 2012
40
[Successful treatment with reduced-intensity cord blood transplantation for acute myeloid leukemia with complete tetraploidy (92, XXXX)]. 61
21471699 2011
41
The HPB-AML-I cell line possesses the properties of mesenchymal stem cells. 61
21144016 2010
42
[Expression of NF-kappaB mRNA in acute myeloid leukemia]. 61
20416168 2010
43
A novel approach to treatment in childhood acute myeloblastic leukemia and myelodysplastic syndrome with high-dose methylprednisolone as a differentiation- and apoptosis-inducing agent of myeloid leukemic cells. 61
27265790 2010
44
[Pyogenic spondylitis following unrelated hematopoietic stem cell transplantation]. 61
20068278 2009
45
Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. 61
19672946 2009
46
A new recurring chromosome 13 abnormality in two older patients with de novo acute myeloid leukemia: An Indian experience. 61
21088719 2009
47
Recurring mutations found by sequencing an acute myeloid leukemia genome. 61
19657110 2009
48
Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II. 61
19236759 2009
49
Jumping translocations in hematological malignancies: a cytogenetic study of five cases. 61
19027489 2008
50
K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML). 61
18587575 2008

Variations for Acute Myeloblastic Leukemia Without Maturation

Expression for Acute Myeloblastic Leukemia Without Maturation

Search GEO for disease gene expression data for Acute Myeloblastic Leukemia Without Maturation.

Pathways for Acute Myeloblastic Leukemia Without Maturation

Pathways related to Acute Myeloblastic Leukemia Without Maturation according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.79 NPM1 FLT3

GO Terms for Acute Myeloblastic Leukemia Without Maturation

Cellular components related to Acute Myeloblastic Leukemia Without Maturation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 8.62 NPM1 FLT3

Biological processes related to Acute Myeloblastic Leukemia Without Maturation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 8.96 NPM1 FLT3
2 viral process GO:0016032 8.62 NPM1 FLT3

Molecular functions related to Acute Myeloblastic Leukemia Without Maturation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 8.62 NPM1 FLT3

Sources for Acute Myeloblastic Leukemia Without Maturation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....